Professor Jonas Bergh, will be leading our scientific advisory board
Stratipath is happy to announce that one of the most prominent breast oncologists, Professor Jonas Bergh, will be leading the company’s scientific advisory board. As Stratipath is entering the clinical phase with its first-in-class, CE-IVD solution for AI-driven risk profiling, Stratipath breast and at the same time ramping up the research and development efforts for future solutions, the scientific advisory board will play a crucial role in the company’s development.
Stratipath wins innovation prize for advances in AI-based precision oncology
AI-precision oncology pioneers Stratipath have been awarded the Athena Prize, one of Sweden’s most prestigious awards for innovation in health care for the development of their AI-based solution for improved prognostic analysis of breast cancer, using only microscopy images.
Stratipath on prestigious startup-list
Stratipath is listed in tech magazine Ny Teknik’s 33-list, which selects the most promising Swedish start-ups each year.
”The path from academic research to precision diagnostics in routine health care” Stratipath co-founder is writing an article about Stratipath and the research behind in ”Oncology Sweden”. (Swedish only)
Read the article (Swedish only)
The Swedish deep-tech company Stratipath announces its integration with Sectra, one of the most expanding PACS systems for digital pathology
Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, today announced that it has released its integration with international medical imaging IT company Sectra and their digital pathology solution. This means that Sectra users can use Stratipath’s solution Stratipath Breast within an already existing digital pathology workflow. The application is featured in Sectra Amplifier Marketplace and purchased directly from Stratipath.
Government grant to provide more accurate breast cancer diagnosis
Vinnova grants SEK 20 million to the Swedish AI Precision Pathology (SwAIPP) consortia to develop and implement AI-based precision diagnostics in cancer care. The consortia consist of Stratipath, Karolinska Institutet, the pathology clinics in the Kalmar, Västmanland and Skåne regions, Microsoft, Roche Diagnostics, Philips, Bröstcancerförbundet, Prevas and Helseplan.
Study shows large variation in biomarkers and grade among Swedish pathology labs calls for AI-supported image analysis
Abstract: We compared estrogen receptor (ER), progesterone receptor (PR), human epidermal growth-factor receptor 2 (HER2), Ki67, and grade scores among the pathology departments in Sweden. We investigated how ER and HER2 positivity rates affect the distribution of endocrine and HER2-targeted treatments among oncology departments. All breast cancer patients diagnosed between 2013 and 2018 in Sweden […]
Stratipath is accepted to the Karolinska Institutet Innovations incubator.
Read the article
